Cell Death and Disease (Aug 2024)

DKK1-SE recruits AP1 to activate the target gene DKK1 thereby promoting pancreatic cancer progression

  • Lan Shao,
  • Haoran Yu,
  • Mengyun Wang,
  • Lu Chen,
  • Boshu Ji,
  • Tong Wu,
  • Xiangqi Teng,
  • Mu Su,
  • Xiao Han,
  • Weikai Shi,
  • Xin Hu,
  • Ziwen Wang,
  • Hongjuan He,
  • Guiping Han,
  • Yan Zhang,
  • Qiong Wu

DOI
https://doi.org/10.1038/s41419-024-06915-z
Journal volume & issue
Vol. 15, no. 8
pp. 1 – 20

Abstract

Read online

Abstract Super-enhancers are a class of DNA cis-regulatory elements that can regulate cell identity, cell fate, stem cell pluripotency, and even tumorigenesis. Increasing evidence shows that epigenetic modifications play an important role in the pathogenesis of various types of cancer. However, the current research is far from enough to reveal the complex mechanism behind it. This study found a super-enhancer enriched with abnormally active histone modifications in pancreatic ductal adenocarcinoma (PDAC), called DKK1-super-enhancer (DKK1-SE). The major active component of DKK1-SE is component enhancer e1. Mechanistically, AP1 induces chromatin remodeling in component enhancer e1 and activates the transcriptional activity of DKK1. Moreover, DKK1 was closely related to the malignant clinical features of PDAC. Deletion or knockdown of DKK1-SE significantly inhibited the proliferation, colony formation, motility, migration, and invasion of PDAC cells in vitro, and these phenomena were partly mitigated upon rescuing DKK1 expression. In vivo, DKK1-SE deficiency not only inhibited tumor proliferation but also reduced the complexity of the tumor microenvironment. This study identifies that DKK1-SE drives DKK1 expression by recruiting AP1 transcription factors, exerting oncogenic effects in PDAC, and enhancing the complexity of the tumor microenvironment.